Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wave Life Sciences ( (WVE) ) has shared an announcement.
On February 26, 2026, Wave Life Sciences reported fourth-quarter and full-year 2025 results, highlighting progress across its RNA-based pipeline and a strong cash position of $602.1 million as of December 31, 2025, providing runway into the third quarter of 2028. Interim data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 showed GLP-1-like fat loss with muscle preservation after a single 240 mg dose, and the company plans to start a Phase 2a multidose trial in higher-BMI patients and additional obesity studies in 2026.
Wave is also advancing its RNA editing assets, including WVE-006 for AATD, where the RestorAATion-2 trial is fully enrolled through the 600 mg cohort with further data readouts expected in 2026 and regulatory feedback on a potential accelerated pathway anticipated mid-year. The company is preparing a 2026 clinical trial application for WVE-008 for PNPLA3 I148M liver disease, remains on track to file a 2026 NDA for Duchenne candidate WVE-N531, and reported that GSK selected a fourth collaboration program in January 2026, supporting ongoing milestone revenue potential.
The most recent analyst rating on (WVE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.
Spark’s Take on WVE Stock
According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish near-term technicals (below key moving averages with negative MACD). These are partially offset by strong earnings-call and corporate-event momentum centered on promising clinical data and extended cash runway/financing support.
To see Spark’s full report on WVE stock, click here.
More about Wave Life Sciences
Wave Life Sciences Ltd., based in Cambridge, Mass., is a clinical-stage biotechnology company specializing in RNA medicines, including RNA interference (RNAi) and RNA editing therapeutics. Its pipeline targets obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease and Duchenne muscular dystrophy, and it collaborates with GSK to develop multiple PRISM platform-based programs.
Average Trading Volume: 6,953,878
Technical Sentiment Signal: Buy
Current Market Cap: $2.57B
For a thorough assessment of WVE stock, go to TipRanks’ Stock Analysis page.